Research by condition

Quitting smoking

Tobacco dependence in people trying to quit.

PsiloAtlas editorial · AI-assisted research summary. Not clinical or medical review. How we research and review

First published October 31, 2026 · Last substantive update November 4, 2026 · Cited sources checked November 4, 2026

What each study tested

Each study is listed with the substance it tested. Results for one substance do not apply to another.

Psilocybin

Johnson et al., Journal of Psychopharmacology, 2014

Design: Open-label pilot study without a comparison group: psilocybin sessions combined with quit-smoking therapy.
Who took part: 15 long-term smokers.
Findings: 12 of 15 participants were abstinent at the six-month follow-up, confirmed with biomarkers.
Limitations: Very small, no control group; the authors say it cannot establish efficacy.

Approval and access, by substance

Research results are not the same as approved or available treatment.

Psilocybin

Not approved by the FDA for any use, and listed in federal Schedule I. Legal adult access in the US exists through Oregon's licensed service centers and Colorado's licensed healing centers, and through clinical trials. Those state programs are not medical treatment programs and do not diagnose or treat conditions. Some countries have separate legal pathways; see the Legal section.

Sources: US Code of Federal Regulations, 21 CFR 1308.11 (Schedule I); Oregon Health Authority, Oregon Psilocybin Services; Colorado Natural Medicine Division, accessing regulated natural medicine

Next steps

General information, not medical advice. Talk to a doctor before any treatment, especially if you take medication or have heart or mental-health conditions.